Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 6/20 | 0.35 |
| ▸ | KDM1B | Q8NB78 | 4/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27130651 | 0.86 | KDM1A (0.36) | KDM1AKDM1BKCNH2NPC1RAB9A | |
| SCHEMBL27007899 | 0.86 | KDM1A (0.36) | KDM1AKDM1BKCNH2NPC1RAB9A | |
| SCHEMBL30745980 | 0.86 | KDM1A (0.36) | KDM1AKDM1BKCNH2NPC1RAB9A | |
| SCHEMBL18502975 | 0.78 | KDM1A (0.36) | KDM1AKDM1BNPC1RAB9AGPR27 | |
| SCHEMBL18302288 | 0.78 | KDM1A (0.36) | KDM1AKDM1BNPC1RAB9AGPR27 | |
| SCHEMBL18302286 | 0.78 | KDM1A (0.36) | KDM1AKDM1BNPC1RAB9AGPR27 | |
| SCHEMBL18502978 | 0.76 | GABRA1 (0.31) | — | |
| SCHEMBL18489289 | 0.76 | GABRA1 (0.31) | — | |
| SCHEMBL30204833 | 0.76 | ESR1 (0.42) | KDM1AKDM1BKCNH2GPR27 | |
| SCHEMBL18489290 | 0.76 | GABRA1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
| WO-2014113485-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2014-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | KDM1A 3743/4885KDM1B 3605/4885KCNH2 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.